|
|
|
This is the preliminary program for the 2008 Joint Statistical
Meetings in Denver, Colorado.
|
|
|
The views expressed here are those of the individual authors and not necessarily those of the ASA or its board, officers, or staff. Back to main JSM 2008 Program page |
= Applied Session,
= Theme Session,
= Presenter|
|
||
215
|
Tue, 8/5/08, 8:30 AM - 10:20 AM | CC-706 |
| New Directions in Safety Planning and Analysis for Clinical Development - Invited - Papers | ||
|
Biopharmaceutical Section, WNAR, Biometrics Section |
||
| Organizer(s): Brenda J. Crowe, Eli Lilly and Company | ||
| Chair(s): Brenda J. Crowe, Eli Lilly and Company | ||
| 8:35 AM |
Regulatory Perspectives on Planning for Pre-Marketing —  George Rochester, U.S. Food and Drug Administration
|
|
| 9:00 AM |
Planning for Meta-Analysis — Jesse A. Berlin, Johnson & Johnson Pharmaceutical R&D, LLC
|
|
| 9:25 AM |
Safety Analyses: Thoughts on Tackling Multiplicity — Devan V. Mehrotra, Merck Research Laboratories; Joseph Heyse, Merck Research Laboratories
|
|
| 9:50 AM |
Detecting Safety Signals in Clinical Trials: A Bayesian Perspective — H. Amy Xia, Amgen, Inc; Haijun Ma, Amgen, Inc; Bradley P. Carlin, The University of Minnesota
|
|
| 10:15 AM | Floor Discussion | |
|
JSM 2008
For information, contact jsm@amstat.org
or phone (888) 231-3473. If you have questions about the Continuing Education program,
please contact the Education Department. |